Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
The point of care testing is also known as beside testing which involves any type of diagnostic test that are not performed in the diagnostic laboratories. More specifically, this type of testing is performed as near as possible to the patients mostly besides the patients or near them and due to that it is named as point of care diagnostics. In other words, point of care testing encompasses any tests that are performed at or near a patient and at the site where care treatment has to be provided. The results of point of care diagnostics are obtained relatively faster than that of the diagnostic laboratories.
The North America point of care diagnostic market is witnessing lucrative growth during the forecast period of 2021 to 2027. The point of care testing enables healthcare staff to make rapid triage and treatment decisions at the time of diagnosis of patient’s condition or monitoring the treatment response of patients. The dynamic factors such as increasing incidences of target conditions is propelling growth of North America point of care diagnostic market. Supportive government policies is also boosting growth of North America point of care diagnostic market. However, pricing pressure owing to reimbursement cuts and budget constraints is restraining growth of North America point of care diagnostic market.
The exclusive COVID-19 impact analysis report by Axiom MRC provides a 3600 analysis of micro and macro-economic factors on the point of care diagnostic market. In addition, complete analysis of changes on point of care diagnostic expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on North America economies, international trade, business investments, GDP and marketing strategies of key players present in the market. The outbreak of COVID-19 has boosted the growth of diagnostic kits for rapid detection of diseases. There is somewhat mismatch between the demand and supply as there is complete shutdown in many countries due to outbreak of COVID-19. The rapidly growing number of COVID-19 cases and the growing pressure on governments for improving patient management has boosted the demand for rapid antigen testing kits which can effectively use in point if care settings.
The North America point of care diagnostic market is bifurcated into test type, mode of prescription, end user and country.
Product type such as glucose monitoring, cardiometabolic monitoring, infectious diseases monitoring, coagulation monitoring, pregnancy and fertility testing, faecal occult testing, haematology testing, tumour/cancer marker testing, urinalysis testing, drug abuse testing and cholesterol testing are comprised in the North America point of care diagnostic market. In which pregnancy and fertility testing is also contributing to the growth of North America point of care diagnostic market. The increasing population of women of reproductive age is propelling growth of North America point of care diagnostic market. The rising awareness of fertility testing among women is also boosting growth of North America point of care diagnostic market.
Mode of prescription such as prescription based and over the counter are comprised in the North America point of care diagnostic market. In which prescription-based products are also projecting the growth of North America point of care diagnostic market. The rising awareness about the use of point of care diagnostic products is propelling growth of North America point of care diagnostic market. The growing prevalence of long term and chronic diseases is also refuelling growth of North America point of care diagnostic market.
End user such as hospitals/critical care centres, ambulatory care settings, research laboratories and home care are comprised in the North America point of care diagnostic market. In which home care segment is also contributing to the growth of the North America point of care diagnostic market. Major factors such as the massive availability of at-home testing kits is propelling growth of North America point of care diagnostic market. Rapid growth in homecare market is also driving growth of North America point of care diagnostic market.
The North America point of care diagnostic market is studied for key countries such as United States, Mexico and Canada. In which United States is anticipated to dominate the market in 2020. The rising technological advancements in healthcare fields is propelling growth of North America point of care diagnostic market. The growing prevalence of chronic diseases is also boosting growth of North America point of care diagnostic market. The growing awareness regarding use of point of care products is also driving growth of North America point of care diagnostic market.
The major key players operating in the market of point of care diagnostic market are Roche Diagnostics, Siemens Healthineers, Danaher Corporation, Becton Dickinson And Company, Abbott Laboratories, Quidel Diagnostics, Chembio Diagnostics, Ekf Diagnostics, Trinity Biotech and Fluxergy among others.
June 2019: Abbott laboratories the launch of Affinion HbA1c Dx Assay. which is a point of care test for diabetes.
June 2019: Quidel Corporation received US FDA approval to commercialize Quidel Triage TOX Drug Screen.
March 2019: Roche Diagnostics FDA approval for the VENTANA PD-L1 (SP142) Assay for identifying triple-negative breast cancer (TNBC) patients.
February 2019: Danaher acquired the Biopharma business of GE Life Sciences with an aim to established as a standalone operating company and strengthen the point of care diagnostics product portfolio.
The report analyses the point of care diagnostic market based on product type, mode of prescription, end user and country. Various types of products available in the point of care market are glucose monitoring, cardiometabolic monitoring, infectious diseases monitoring, coagulation monitoring, pregnancy and fertility testing, faecal occult testing, haematology testing, tumour/cancer marker testing, urinalysis testing, drug abuse testing and cholesterol testing. By mode of prescription, the market is segmented into the prescription based and over the counter products. Based on end users, the market is segmented into the hospital/critical care centres, ambulatory care settings, research laboratory and home care. The study also analyses the impact of COVID-19 on the point of care diagnostic market and it founds that the outbreak of COVID-19 has boosted the growth of diagnostic kits for rapid detection of diseases. There is somewhat mismatch between the demand and supply as there is complete shutdown in many countries due to outbreak of COVID-19. The rapidly growing number of COVID-19 cases and the growing pressure on governments for improving patient management has boosted the demand for rapid antigen testing kits which can effectively use in point if care settings. The study also analyses various major key players operating in the market.
Why to buy this report
